Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Table 4 Correlations between TILs and pCR in clinicopathologic subgroups

Variable	No. of patients	Per 10% sTILs increase			Per 10% iTILs increase
Variable	No. of patients	Adjusted OR	95% CI	P-value*	Adjusted OR	95% CI	P-value*
Age (years)
< 50	80	1.06	1.01–1.11	0.78	1.09	1.01–1.18	0.64
≥ 50	86	1.07	1.02–1.12	0.78	1.12	1.03–1.22	0.64
Tumor size (cm)
≤ 2	22	1.05	0.99–1.12	0.68	1.07	0.92–1.25	0.72
2–5	115	1.06	1.02–1.10		1.09	1.02–1.16
> 5	29	1.11	1.00–1.24		1.16	1.00–1.35
Lymph node status
Negative	53	1.07	1.00–1.14	0.81	1.07	0.96–1.18	0.56
Positive	113	1.06	1.02–1.10	0.81	1.11	1.04–1.19	0.56
Grade
2	31	1.01	0.90–1.13	0.34	1.02	0.84–1.23	0.46
3	135	1.07	1.03–1.10	0.34	1.11	1.04–1.17	0.46
LVI
Negative	130	1.06	1.02–1.10	0.49	1.08	1.02–1.15	0.84
Positive	36	1.14	0.93–1.39	0.49	1.11	0.83–1.48	0.84
NAC
Anthracycline + paclitaxel	136	1.07	1.03–1.12	0.23	1.12	1.06–1.20	0.14
Paclitaxel + platinum	30	1.01	0.93–1.10	0.23	1.00	0.87–1.14	0.14

Abbreviations: pCR pathological complete response, sTILs stromal tumor-infiltrating lymphocytes, iTILs intratumoral tumor-infiltrating lymphocytes, LVI lymphovascular invasion, NAC neoadjuvant chemotherapy, OR odds ratio, 95% CI 95% confidence interval
*The chi-squared test

ISSN: 1746-1596